ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

David Vicente-Baz,Alfredo Paredes,Teresa Morán,Bartomeu Massuti,Noemí Reguart,Rosa Álvarez,Amelia Insa,Oscar Juan-Vidal,Ángel Artal,Emilio Esteban,Rosario García-Campelo, Ana L. Ortega-Granados,Pilar Diz,Jose L. González-Larriba,Josefa Terrasa,Ramón de las Peñas,Delvys Rodríguez-Abreu,Ángel Callejo,Gloria Márquez,Mariano Provencio

Revista Española de Patología（2020）

引用 0|浏览14

暂无评分

摘要

ASTRIS is expected to confirm the benefits of osimertinib in a real-world setting. Data on real-world practices for the detection of the EGFR T790M mutation may provide additional information for the designing of guidelines for best practices.

查看译文

关键词

Osimertinib,Tyrosine kinase inhibitor,EGFR T790M mutation,Non-small cell lung cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要